| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities | |||||||||
Net loss | |||||||||
-363,012 | -212,526 | 11,109 | -63,937 | -50,074 | -34,657 | -21,911 | - | - | - |
Net loss | |||||||||
- | - | - | - | - | - | - | -4,845 | -3,236 | -1,808 |
Adjustments to reconcile net loss to net cash used for operating activities: | |||||||||
Depreciation and amortization | |||||||||
10,989 | 9,494 | 7,138 | 2,885 | 2,370 | 3,184 | 1,290 | 293 | - | - |
Non-cash operating lease cost | |||||||||
4,053 | - | - | - | - | - | - | - | - | - |
Non-cash interest expense and amortization of debt issuance costs | |||||||||
22,526 | 53,391 | 1,803 | 164 | 392 | 451 | 0 | 0 | - | - |
Acquired in-process research and development | |||||||||
75,301 | 9,895 | 0 | 0 | 12,000 | 209 | 1,905 | - | - | - |
Loss on trading securities | |||||||||
-203 | -144 | -665 | - | - | - | - | - | - | - |
Gain on sale of IgDraSol | |||||||||
- | - | - | - | 69,274 | 0 | 0 | - | - | - |
Amortization of debt issuance costs and debt discount | |||||||||
- | - | - | 0 | 0 | - | - | - | - | - |
(Gain) loss on sale of marketable securities | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Loss on trading securities | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Gain on sale of marketable securities | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Loss (gain) on sale of marketable securities | |||||||||
- | - | - | 27,193 | - | - | - | - | - | - |
Loss (gain) on sale of marketable securities | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Depreciation and amortization | |||||||||
- | - | - | - | - | - | - | - | 159 | 23 |
Stock-based compensation | |||||||||
12,648 | 6,206 | 4,952 | 4,741 | 6,972 | 3,940 | 1,789 | 863 | 298 | 250 |
Acquired in-process research and development | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Provision for doubtful accounts | |||||||||
- | - | - | - | 5 | 33 | 0 | 0 | - | - |
Loss on disposal for property and equipment | |||||||||
- | - | - | 0 | 0 | - | - | - | - | - |
Loss on receivable | |||||||||
- | - | - | 0 | 0 | - | - | - | - | - |
Loss on debt settlement / extinguishment | |||||||||
-27,810 | -8,089 | -4,275 | 0 | 0 | - | - | - | - | - |
(Gain) Loss on derivative liabilities | |||||||||
-36,800 | 2,830 | 0 | 5,520 | -3,360 | 0 | - | - | - | - |
Loss on equity method investments | |||||||||
-3,909 | -5,019 | -40,244 | 435 | -4,041 | - | - | - | - | - |
Non-cash income on cost method investments | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Loss on derivative liabilities | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Loss on equity method investments | |||||||||
- | - | - | - | - | 0 | 0 | - | - | - |
Non-cash income on cost method investments | |||||||||
0 | 0 | 116,249 | 0 | - | - | - | - | - | - |
(Gain) Loss on contingent liabilities and acquisition consideration payable | |||||||||
-11,090 | 9,644 | 0 | - | - | - | - | - | - | - |
Loss on contingent liabilities and acquisition consideration payable | |||||||||
- | - | - | -8,121 | 0 | 0 | - | - | - | - |
Loss on IPR&D impairment | |||||||||
0 | 1,826 | 0 | 0 | - | - | - | - | - | - |
Deferred tax provision | |||||||||
-373 | -6,119 | -35,679 | 982 | 33,337 | - | - | - | - | - |
Deferred tax provision | |||||||||
- | - | - | - | - | -1,702 | 0 | 0 | - | - |
Changes in operating assets and liabilities, excluding effect of acquisitions: | |||||||||
Accounts receivable | |||||||||
10,622 | 1,623 | 515 | 472 | 176 | 371 | -117 | 18 | - | - |
Accrued payroll | |||||||||
5,678 | 5,751 | 920 | 0 | 0 | - | - | - | - | - |
Grants and accounts receivable | |||||||||
- | - | - | - | - | - | - | - | -184 | 246 |
Prepaid expenses, deposits and other assets | |||||||||
517 | 2,804 | 1,669 | -40 | 1,052 | 979 | 441 | 77 | -15 | 17 |
Deposits and other assets | |||||||||
- | - | - | 448 | 1,715 | 0 | - | - | - | - |
Income tax receivable | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Accounts payable | |||||||||
10,221 | 3,578 | 1,592 | 3,714 | -2,713 | -497 | 878 | -23 | 42 | -104 |
Acquisition consideration payable | |||||||||
0 | -2,020 | 0 | 0 | - | - | - | - | - | - |
Acquisition consideration payable for Scilex | |||||||||
- | - | - | - | - | - | - | - | -7 | 185 |
Accrued expenses and other liabilities | |||||||||
4,061 | 6,130 | 2,323 | 1,673 | 10,582 | 1,625 | -116 | 10 | - | - |
Deferred revenue | |||||||||
-945 | -3,263 | -20,891 | 23,534 | - | - | - | - | - | - |
Accounts payable-related parties | |||||||||
- | - | - | - | - | - | - | - | - | -30 |
Deferred revenue | |||||||||
- | - | - | - | - | - | - | - | -200 | 200 |
Deferred revenue | |||||||||
- | - | - | - | 9,876 | 0 | 0 | - | - | - |
Other | |||||||||
-628 | 251 | 802 | -2,535 | 0 | 0 | - | - | - | - |
Net cash used for operating activities | |||||||||
- | - | - | - | - | -28,764 | -16,489 | -3,797 | - | - |
Net cash used for operating activities | |||||||||
-172,996 | -111,767 | -99,180 | -70,928 | -42,069 | - | - | - | -2,743 | -1,546 |
Investing activities | |||||||||
Purchases of property and equipment | |||||||||
11,442 | 11,195 | 10,972 | 6,860 | 3,707 | 591 | 420 | 548 | 1,051 | 46 |
Purchase of assets related to Semnur, net of cash acquired | |||||||||
17,040 | 0 | 0 | - | - | - | - | - | - | - |
Proceeds from sale of IgDraSol | |||||||||
- | - | - | - | -27,759 | - | - | - | - | - |
Purchase of assets related to Semnur, net of cash acquired | |||||||||
- | - | - | 0 | - | - | 511 | 0 | - | - |
Cash received in connection with mergers | |||||||||
- | - | - | - | - | - | 428 | 0 | - | - |
Investments | |||||||||
- | - | - | - | 11,500 | 10,000 | 0 | 0 | - | - |
Other acquisitions and investments | |||||||||
9,691 | 10,000 | 5,557 | 3,842 | 0 | 0 | - | - | - | - |
Net cash used in investing activities | |||||||||
- | - | - | - | - | -10,591 | -503 | -548 | - | - |
Net cash used for investing activities | |||||||||
-38,173 | -21,195 | -16,529 | -17,452 | 12,552 | - | - | - | -1,051 | -46 |
Financing activities | |||||||||
Proceeds from equity offerings, net of issuance costs | |||||||||
- | - | - | 107,986 | 0 | 71,786 | 37,701 | 5,934 | 1,970 | 3,440 |
Payments on bridge loans and Scilex Notes | |||||||||
3,074 | 20,000 | 0 | - | - | - | - | - | - | - |
Proceeds from 2017 Securities Purchase Agreement, net of issuance costs | |||||||||
0 | 0 | 49,916 | - | - | - | - | - | - | - |
Proceeds from short-term debt | |||||||||
8,000 | 21,261 | 0 | 0 | - | - | - | - | - | - |
Sale of a noncontrolling interest | |||||||||
- | - | - | - | 49 | 0 | 0 | - | - | - |
Proceeds from exercise of stock options and warrants | |||||||||
8,851 | 211 | 0 | 524 | 1,699 | 304 | 17 | 36 | 13 | - |
Cash payments for treasury shares | |||||||||
- | - | - | 15,639 | 0 | 0 | - | - | - | - |
Proceeds from loan and security agreement, net of fees | |||||||||
- | - | - | 48,320 | -3,095 | 0 | - | - | - | - |
Payments of debt on retired note | |||||||||
- | - | - | 9,451 | 0 | 0 | - | - | - | - |
Repayments of debt and other obligations | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Proceeds from issuance of Scilex notes, net of issuance costs | |||||||||
0 | 134,275 | 0 | 0 | - | - | - | - | - | - |
Scilex notes issuance of Scilex notes | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Proceeds from issuance of convertible notes | |||||||||
0 | 37,849 | 0 | 0 | - | - | - | - | - | - |
Payment of Hercules Loan Agreement | |||||||||
0 | 0 | 53,157 | - | - | - | - | - | - | - |
Scilex consideration for regulatory milestones | |||||||||
0 | 22,466 | 0 | 0 | - | - | - | - | - | - |
Net payments of deferred compensation | |||||||||
0 | 0 | 1,012 | 0 | 2,000 | 0 | 1,000 | 0 | - | - |
Net borrowings under loan and security agreement | |||||||||
- | - | - | 0 | 0 | 7,500 | 6,850 | 0 | - | - |
Repayment of bridge loan for Scilex regulatory milestone | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Proceeds from Oaktree Term Loans, net of issuance costs | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Net cash provided by (used for) financing activities | |||||||||
78,885 | 325,998 | 53,675 | 131,740 | -3,347 | - | - | - | 1,984 | 3,440 |
Net change in cash, cash equivalents and restricted cash | |||||||||
-132,284 | 193,036 | -62,034 | 43,360 | - | - | - | - | - | - |
Net effect of exchange rate changes on cash | |||||||||
-277 | -135 | 65 | 0 | - | - | - | - | - | - |
Supplemental disclosures: | |||||||||
Cash paid during the period for: | |||||||||
Income taxes | |||||||||
13 | 6 | 34 | 2 | 3,001 | 6 | 1 | 1 | 0 | 1 |
Interest | |||||||||
12,738 | 1,620 | 3,499 | 1,342 | - | - | - | - | - | - |
Interest paid | |||||||||
- | - | - | - | 1,574 | 1,544 | 0 | 0 | - | - |
Supplemental disclosures of non-cash investing and financing activities: | |||||||||
Semnur acquisition consideration paid in equity | |||||||||
54,591 | 0 | 0 | - | - | - | - | - | - | - |
Semnur acquisition costs incurred but not paid | |||||||||
601 | 0 | 0 | - | - | - | - | - | - | - |
Change in unrealized gains or (losses) on marketable securities | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Conversion of convertible notes | |||||||||
-53,983 | -50,000 | 0 | 0 | 100,000 | 0 | 0 | - | - | - |
Loss on debt extinguishment | |||||||||
- | 9,646 | 12,669 | - | - | - | - | - | - | - |
Contributions to equity method investments made on Company's behalf | |||||||||
- | - | - | - | 60,000 | 0 | - | - | - | - |
Contributions to equity method investments made on Company's behalf | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Property and equipment costs incurred but not paid | |||||||||
849 | 328 | 37 | 0 | 2,396 | 0 | 0 | - | - | - |
Reconciliation of cash, cash equivalents and restricted cash within the Company’s consolidated balance sheets: | |||||||||
Net cash provided by financing activities | |||||||||
- | - | - | - | - | 79,590 | 43,568 | 5,970 | - | - |
Net change in cash and cash equivalents | |||||||||
- | - | - | - | -32,864 | 40,235 | - | - | - | - |
Net effect of exchange rate changes on cash | |||||||||
- | - | - | - | 0 | 0 | - | - | - | - |
Net change in cash and cash equivalents | |||||||||
- | - | - | - | - | - | 26,576 | 1,625 | -1,811 | 1,847 |
Sini West | |||||||||
Payments to Investments | |||||||||
- | - | - | 1,000 | - | - | - | - | - | - |
Non-cash consideration received | |||||||||
- | - | - | 2,832 | - | - | - | - | - | - |
Celularity Inc | |||||||||
Payments to Investments | |||||||||
- | - | - | 5,000 | - | - | - | - | - | - |
MedoveX | |||||||||
Payments to Investments | |||||||||
- | - | - | 750 | - | - | - | - | - | - |
Public Offering Of Common Stock And Warrants 2019 | |||||||||
Proceeds from equity offerings, net of issuance costs | |||||||||
46,707 | 0 | 0 | - | - | - | - | - | - | - |
Milestones Achievement | |||||||||
Bridge loan for Scilex settlement | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Payments on short term bridge loan | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
ATM Facility | |||||||||
Proceeds from issuance of common stock | |||||||||
- | 83,608 | 57,928 | - | - | - | - | - | - | - |
Distribution Agreement | |||||||||
Proceeds from issuance of common stock | |||||||||
990 | - | - | - | - | - | - | - | - | - |
Oaktree Term Loan | |||||||||
Scilex notes issuance of Scilex notes | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Proceeds from Oaktree Term Loans, net of issuance costs | |||||||||
17,411 | 91,260 | 0 | 0 | - | - | - | - | - | - |
Virttu Biologics Limited | |||||||||
Non-cash consideration given | |||||||||
0 | 11,308 | 15,465 | 0 | - | - | - | - | - | - |
Scilex Pharmaceuticals, Inc | |||||||||
Non-cash consideration given | |||||||||
0 | 13,744 | 1,380 | 0 | - | - | - | - | - | - |
Non-cash consideration received | |||||||||
- | - | - | 45,368 | - | - | - | - | - | - |
Roger Williams Medical Center | |||||||||
Non-cash consideration received | |||||||||
- | - | - | 3,398 | - | - | - | - | - | - |
BDL | |||||||||
BDL stock issuance | |||||||||
0 | 2,340 | 0 | 0 | - | - | - | - | - | - |
ImmuneOncia Therapeutics, LLC | |||||||||
Investment in ImmuneOncia | |||||||||
- | - | - | 9,608 | - | - | - | - | - | - |
June 2018 Warrants, Amendment | |||||||||
Loss on debt extinguishment | |||||||||
0 | 1,916 | 0 | 0 | - | - | - | - | - | - |